Early human clinical trial results suggest that a better drug for lowering bad cholesterol may be on the horizon.
Calls for prescription drug reform blast the original biotech blue-chip stock in September. Could Amgen have more downside to come, or is this latest dip an early holiday gift?
Amgen and Allergan's ABP 215 biosimilar to Avastin posted positive results in phase 3 trials.
As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.
AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.
The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.
These three companies have the potential to double their share price from current levels. Here's why.
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.